XW043H6
Introduction Central Vein to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 4 Central Vein |
| Approach | 3 Percutaneous |
| Device | H Other New Technology Monoclonal Antibody |
| Qualifier | 6 New Technology Group 6 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Central Vein
Central veins, including the vena cavae and other large-caliber vessels near the heart, provide access for substances that require rapid dilution, higher infusion volumes, or delivery closer to central circulation than a peripheral vein allows. Introduction procedures coded here under New Technology reflect administration of a novel agent through this central route, which is often chosen when a substance is irritating to smaller vessels or needs to reach systemic circulation quickly and at high concentration. Central venous access typically requires a dedicated catheter placed under imaging or landmark guidance, and the procedure carries different risks, including central line infection, compared with peripheral administration. Coding accuracy depends on documenting that central rather than peripheral venous access was used for the introduced substance.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Other New Technology Monoclonal Antibody
This code captures a monoclonal antibody administered under the New Technology section that is not individually identified elsewhere in the classification, functioning as a catch-all for newly introduced or otherwise unlisted antibody products. It differs from the named monoclonal antibodies in this list, such as leronlimab or epcoritamab, each of which has its own specific code reflecting a distinct target and clinical indication, whereas this value carries no such specificity.
Qualifier: New Technology Group 6
This value marks Group 6, the cohort of new technologies added for the 2019-2020 fiscal year. As with every group qualifier in this section, it is a bookkeeping label showing when a technology earned a distinct code rather than a clue to its function, which is conveyed through the accompanying device or substance value. It should not be read as interchangeable with Group 5 or Group 7.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.